美國CytoGenix www.cytogenix.com
CytoGenix和Omnimmune簽定了一項研發(fā)合作協(xié)議，它們將把CytoGenix的細胞內表達技術和Omnimmune的單克隆抗體結合起來，以促進用于診斷、預后、控制和防治癌癥的基因制品的輸送和靶向性。
CytoGenix的技術可生產(chǎn)未修飾的單鏈DNA(ssDNA)，這些ssDNA用于與反義技術、三聯(lián)技術、DNA疫苗和aptamer相關的催化和治療應用。而Omnimmune的技術將提高CytoGenix的載體對特定細胞系的靶向性，促進細胞對載體的攝取，并在細胞內復制多個特定ssDNA序列。
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative compounds and services based on its proprietary gene regulating and DNA production technologies. CytoGenix has products in pre-clinical development including an antimicrobial compound, DNA vaccines and anti-herpes and anti-inflammatory topical creams. The Company has developed a cell free process for synthesizing DNA which it uses for its own products as well as marketing specific compounds to other companies. CytoGenix, Inc. currently has 11 granted patents (1 US, 1 China, 9 Europe) covering our basic ssDNA expression technology, with one additional allowance (India) pending. We have an additional 11 applications pending in various countries which are currently progressing through the normal prosecution process. The Company actively collaborates with numerous academic centers of excellence, government agencies and biotechnology industry partners. Cytogenix, Inc. is publicly traded under the symbol CYGX on the NASDAQ Over the Counter Bulletin Board.